Related Experiment Videos
A case study: nonsteroidal antiinflammatory drugs and gastrointestinal bleeding
1Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick 08903-0019.
The Journal of Rheumatology. Supplement
|October 1, 1988
Summary
Nonsteroidal anti-inflammatory drugs (NSAID) increase the risk of upper gastrointestinal bleeding by 1.5 times. Sulindac showed a higher bleeding rate compared to other NSAIDs in this drug surveillance study.
Area of Science:
- Pharmacovigilance
- Gastroenterology
- Drug Safety
Background:
- Nonsteroidal anti-inflammatory drugs (NSAID) are widely used for pain and inflammation.
- Upper gastrointestinal (GI) bleeding is a known potential adverse effect of NSAID use.
Purpose of the Study:
- To investigate the association between NSAID exposure and upper GI bleeding.
- To compare the risk of upper GI bleeding among different NSAIDs, specifically identifying if certain drugs pose a higher risk.
Main Methods:
- A postmarketing drug surveillance study design was employed.
- Comparative analysis of upper GI bleeding rates between NSAID-exposed and unexposed patient cohorts.
- Analysis of bleeding rates among patients exposed to single NSAID agents.
Main Results:
- NSAID exposure was associated with a 1.5-fold increased risk of upper GI bleeding (95% CI, 1.2-2.0).
- Significant dose-response (p<0.01) and duration-response (p<0.001) relationships were observed.
- Sulindac was linked to the highest rate of upper GI bleeding among individual NSAIDs, even after controlling for confounding variables.
Conclusions:
- NSAID use is significantly associated with an increased risk of upper GI bleeding.
- Sulindac may be associated with a higher frequency of upper GI bleeding compared to other NSAIDs.
- These findings highlight the importance of continued drug safety monitoring for NSAIDs.